LONDON, Nov. 8, 2019 /PRNewswire/ -- Smith+Nephew
(LSE:SN, NYSE:SNN), the global medical technology business, today
announces the launch of its OR3O Dual Mobility System for use in
primary and revision hip arthroplasty. Compared with traditional
solutions, dual mobility implants have a small diameter femoral
head that locks into a larger polyethylene insert - increasing
stability and offering improved range of motion.1
Since its introduction in 2010, the dual mobility segment has
grown rapidly, and today 9% of primary hip arthroplasty procedures
and 28% of revisions in the American Joint Registry utilized a dual
mobility device.2
OR3O incorporates Smith+Nephew's latest advanced bearing
surface, OXINIUM DH (Diffusion Hardened), for its liner as well as
its proprietary VERILAST™ Technology for its femoral head and
polyethylene inserts. OXINIUM Technology has been shown to deliver
significant reductions in wear compared to Cobalt Chrome (CoCr),
the material used in most competitive products.3
"The OR3O Dual Mobility System is truly a fourth generation dual
mobility offering by introducing OXINIUM technologies. This is a
solution that allows patients to get back to their lives by
providing stability and offers unique advantages compared to other
systems," said Stephen Duncan, MD an orthopedic surgeon at the
University of Kentucky.
"Our new OR3O Dual Mobility System is a groundbreaking product
that offers technology not available in competitive
systems," said Skip Kiil, President of Orthopaedics at
Smith+Nephew. "The proven success of our VERILAST Technology and
OXINIUM DH bearing surface set OR3O apart as a game changing
solution in the hip arthroplasty market."
OXINIUM DH is the newest addition to Smith+Nephew's OXINIUM
platform and increases the depth of hardening through a patented
technology process. It is designed specifically to address hip
arthroplasty needs.
Smith+Nephew's OR3O Dual Mobility System is available in
the United States for both primary
and revision applications and offers cross-compatibility with the
R3 and REDAPT acetabular systems.
References
- Darrith B, Courtney P.M., Della Valle
C.J. Outcomes of dual mobility components in total hip
arthroplasty. Bone Joint J 2018;100-B:11–19.
- Heckmann N, Ihn H, Stefl M, et al. Early Results From the
American Joint Replacement Registry: A Comparison With Other
National Registries. Journal of Arthroplasty. 2019;34(7,
Suppl):S125-34.e1
- Parikh A, Hill P, Pawar V, Sprague J.
Long-term simulator wear performance of an advanced bearing
technology for THA. Poster: 1028. ORS 2013.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology business that exists to restore people's bodies and
their self-belief by using technology to take the limits off
living. We call this purpose 'Life Unlimited'. Our 16,000+
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Advanced
Wound Management and Sports Medicine & ENT. Founded in
Hull, UK, in 1856, we now operate
in more than 100 countries, and generated annual sales of
$4.9 billion in 2018. Smith+Nephew is
a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group'
and 'Smith+Nephew' are used to refer to Smith & Nephew
plc and its consolidated subsidiaries, unless the context
requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: economic
and financial conditions in the markets we serve, especially those
affecting health care providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or other
problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; disruption to our supply chain or operations
or those of our suppliers; competition for qualified personnel;
strategic actions, including acquisitions and dispositions, our
success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic,
business, competitive or reputational nature. Please refer to the
documents that Smith+Nephew has filed with the U.S. Securities and
Exchange Commission under the U.S. Securities Exchange Act of 1934,
as amended, including Smith+Nephew's most recent annual report on
Form 20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/smithnephew-launches-industry-first-or3o-dual-mobility-system-utilising-unique-oxinium-dh-metal-alloy-for-use-in-primary-and-revision-hip-arthroplasty-300954530.html
SOURCE Smith+Nephew